Serhat Bor1, Doga Capanoglu2, Rukiye Vardar3, Andrew D Woodcock4, Jeanine Fisher5, Peter William Dettmar6. 1. Section of Gastroenterology, Ege University School of Medicine, Ege Reflux Study Group, Izmir, Turkey. . serhat.bor@ege.edu.tr. 2. Section of Gastroenterology, Ege University School of Medicine, Ege Reflux Study Group, Izmir, Turkey. dogacapan@gmail.com. 3. Section of Gastroenterology, Ege University School of Medicine, Ege Reflux Study Group, Izmir, Turkey. rukiye.vardar@ege.edu.tr. 4. RD Biomed Limited, Castle Hill Hospital, United Kingdom. andrew.woodcock@rdbiomed.com. 5. RD Biomed Limited, Castle Hill Hospital, United Kingdom. jeanine.fisher@technostics.com. 6. RD Biomed Limited, Castle Hill Hospital, United Kingdom. peter.dettmar@rdbiomed.com.
Abstract
BACKGROUND AND AIMS: Pepsin in the gastric refluxate is a marker for a prior reflux event and rapid detection might be achieved using the Peptest™, an in vitro diagnostic medical device. The aim of this study was to validate the use of Peptest™ to reliably diagnose reflux in patients with gastro-esophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR) disease diagnosed with multichannel intraluminal impedance/ pHmetry (MII-pH). METHODS: 20 reflux patients were recruited of whom 10 had classical GERD and 10 had LPR. All patients underwent MII-pH and provided expectorated saliva samples when a MII-pH reflux event was observed, or reflux symptoms were experienced, and all were tested for the presence of pepsin using the Peptest™. RESULTS: Pepsin was detected in 31 out of 45 samples (68.9%). At least 1 positive pepsin result was seen in 16 patients (80%) and this was the same, irrespective of the GERD or LPR diagnosis. Peptest™ had a positive predictive value of 69% to detect MII-pH reflux events. CONCLUSIONS: Peptest™ is a good first-line diagnostic procedure to use in reflux sufferers to confirm the presence of reflux.
BACKGROUND AND AIMS: Pepsin in the gastric refluxate is a marker for a prior reflux event and rapid detection might be achieved using the Peptest™, an in vitro diagnostic medical device. The aim of this study was to validate the use of Peptest™ to reliably diagnose reflux in patients with gastro-esophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR) disease diagnosed with multichannel intraluminal impedance/ pHmetry (MII-pH). METHODS: 20 reflux patients were recruited of whom 10 had classical GERD and 10 had LPR. All patients underwent MII-pH and provided expectorated saliva samples when a MII-pH reflux event was observed, or reflux symptoms were experienced, and all were tested for the presence of pepsin using the Peptest™. RESULTS: Pepsin was detected in 31 out of 45 samples (68.9%). At least 1 positive pepsin result was seen in 16 patients (80%) and this was the same, irrespective of the GERD or LPR diagnosis. Peptest™ had a positive predictive value of 69% to detect MII-pH reflux events. CONCLUSIONS: Peptest™ is a good first-line diagnostic procedure to use in reflux sufferers to confirm the presence of reflux.